Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dean Rudge

Senior Reporter

London, UK

Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries in his five years with Generics bulletin. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent-infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.

Latest From Dean Rudge

Rosemont Celebrates One Year Of Independence With 49% Growth

A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.

Generic Drugs Sales & Earnings

Catalent Joins Civica’s New Business Arm For Generic Manufacturing

CDMO Catalent and US health insurance giant Anthem have joined up with non-profit Civica’s new outpatient-focused generics business arm, CivicaScript, with plans to begin rolling out products as early as next year.

Generic Drugs Manufacturing

Court Ruling Gives Sandoz Canada First Generic Pirfenidone

A favorable court ruling has allowed Sandoz Canada to launch the first generic version of Roche’s Esbriet to treat idiopathic pulmonary fibrosis.

Generic Drugs Launches

Alvotech Adalimumab Biosimilar Switching Study Hits Key Date

Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.

Biosimilars Clinical Trials

Glenmark Fulfills Promise To Introduce Tiotropium In Europe

India’s Glenmark had noted recently that market entry was forthcoming for a generic Boehringer Ingelheim’s Spiriva Handihaler, and has now delivered with an initial UK launch.

Launches Generic Drugs

Breckenridge Eyes First Kyprolis Generic With FDA Approval

Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.

Approvals Generic Drugs
See All
UsernamePublicRestriction

Register